Tina Costacou1, Aaron M Secrest2, Robert E Ferrell3, Trevor J Orchard4. 1. Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, USA costacout@edc.pitt.edu. 2. Department of Dermatology, University of Utah, Salt Lake City, UT, USA. 3. Department of Human Genetics, University of Pittsburgh, Pittsburgh, PA, USA. 4. Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, USA.
Abstract
OBJECTIVE: We prospectively evaluated the haptoglobin (Hp)-stroke association in type 1 diabetes and hypothesized that despite increasing the risk of coronary artery disease, the presence of the Hp 2 allele would be associated with a lower incidence of stroke. METHODS: Participants from the Epidemiology of Diabetes Complications study without prevalent stroke and Hp available were evaluated (n = 607; mean age 27.6 years and duration 19.3 years). RESULTS: During 22 years of follow-up, stroke incidence did not differ by Hp genotype (p = 0.49). Restricting analyses to those diagnosed with diabetes ≥1965 (13% mortality vs 40% in the <1965 cohort) to diminish potential survival bias, the adjusted hazard ratio (HR) for Hp 1-1 was 3.08 (95% confidence interval (CI) = 0.81-11.77, p = 0.10). Further stratifying by hypertension prevalence, an increased stroke incidence was observed with Hp 1-1 only in those with hypertension (HR = 7.03, 95% CI = 1.42-34.89, p = 0.02). CONCLUSION: Despite the protective effect against vascular diabetes complications, a borderline increased risk of stroke was observed with Hp 1-1 in type 1 diabetes. This mixed Hp effect on cardiovascular risk by outcome studied merits further investigation and cautions against the universal application of preventive therapies across all Hp genotypes.
OBJECTIVE: We prospectively evaluated the haptoglobin (Hp)-stroke association in type 1 diabetes and hypothesized that despite increasing the risk of coronary artery disease, the presence of the Hp 2 allele would be associated with a lower incidence of stroke. METHODS:Participants from the Epidemiology of Diabetes Complications study without prevalent stroke and Hp available were evaluated (n = 607; mean age 27.6 years and duration 19.3 years). RESULTS: During 22 years of follow-up, stroke incidence did not differ by Hp genotype (p = 0.49). Restricting analyses to those diagnosed with diabetes ≥1965 (13% mortality vs 40% in the <1965 cohort) to diminish potential survival bias, the adjusted hazard ratio (HR) for Hp 1-1 was 3.08 (95% confidence interval (CI) = 0.81-11.77, p = 0.10). Further stratifying by hypertension prevalence, an increased stroke incidence was observed with Hp 1-1 only in those with hypertension (HR = 7.03, 95% CI = 1.42-34.89, p = 0.02). CONCLUSION: Despite the protective effect against vascular diabetes complications, a borderline increased risk of stroke was observed with Hp 1-1 in type 1 diabetes. This mixed Hp effect on cardiovascular risk by outcome studied merits further investigation and cautions against the universal application of preventive therapies across all Hp genotypes.
Authors: Andrew P Levy; Irit Hochberg; Kathleen Jablonski; Helaine E Resnick; Elisa T Lee; Lyle Best; Barbara V Howard Journal: J Am Coll Cardiol Date: 2002-12-04 Impact factor: 24.094
Authors: T J Orchard; J S Dorman; R E Maser; D J Becker; A L Drash; D Ellis; R E LaPorte; L H Kuller Journal: Diabetes Date: 1990-09 Impact factor: 9.461
Authors: Susan P Laing; Anthony J Swerdlow; Lucy M Carpenter; Stefan D Slater; Andrew C Burden; Johannes L Botha; Andrew D Morris; Norman R Waugh; Wendy Gatling; Edwin A M Gale; Christopher C Patterson; Zongkai Qiao; Harry Keen Journal: Stroke Date: 2003-02 Impact factor: 7.914
Authors: J R Delanghe; D A Duprez; M L De Buyzere; B M Bergez; B Y Callens; G G Leroux-Roels; D L Clement Journal: J Hypertens Date: 1993-08 Impact factor: 4.844
Authors: Werner Koch; Wolfgang Latz; Marianne Eichinger; Ariel Roguin; Andrew P Levy; Albert Schömig; Adnan Kastrati Journal: Clin Chem Date: 2002-09 Impact factor: 8.327
Authors: Hazel Mae A Abraham; Leslie Wolfson; Nicola Moscufo; Charles R G Guttmann; Richard F Kaplan; William B White Journal: J Cereb Blood Flow Metab Date: 2016-01 Impact factor: 6.200
Authors: Leah E Cahill; Majken K Jensen; Stephanie E Chiuve; Hadar Shalom; Jennifer K Pai; Alan J Flint; Kenneth J Mukamal; Kathryn M Rexrode; Andrew P Levy; Eric B Rimm Journal: J Am Coll Cardiol Date: 2015-10-20 Impact factor: 24.094
Authors: Tina Costacou; Caterina Rosano; Howard Aizenstein; Joseph M Mettenburg; Karen Nunley; Robert E Ferrell; Trevor J Orchard Journal: Diabetes Date: 2014-09-11 Impact factor: 9.461